Prima's ovarian cancer drug wins fast-track status from FDA

05/9/2014 | Australian Life Scientist

The FDA has granted fast-track designation to Prima BioMed's experimental drug CVac as a treatment for relapsed platinum-sensitive epithelial ovarian cancer. The drug also holds orphan drug status in both the U.S. and Europe. The designation is an "important milestone" for Prima and a "recognition of the serious nature of ovarian cancer and the clear unmet medical need to develop new treatments for relapsed platinum-sensitive ovarian cancer in remission," CEO Matthew Lehman said.

View Full Article in:

Australian Life Scientist

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA